Activity of Novel Antimicrobials against Gram-Negative Clinical Pathogens and Characterization of Their Resistance Mechanisms
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: 15 May 2024 | Viewed by 246
Special Issue Editors
2. Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy
Interests: acquired resistance mechanisms; novel antibiotics; evaluation of diagnostic systems for antimicrobial susceptibility testing; whole-genome sequencing; gram-negatives, CPE; genotypic characterization of outbreak
Special Issue Information
Dear Colleagues,
The increase in infections caused by bacterial pathogens resistant to most available antibiotics has a significant impact on global health. In 2016, the World Health Organization enumerated a priority list of 12 species for which the discovery of new antibiotics was urgently required, including multidrug-resistant and carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, as well as carbapenem-resistant and/or third-generation cephalosporin-resistant Enterobacteriaceae. Therefore, in the last few years, several novel agents were approved by medicine regulatory agencies, while others are in late clinical development. The combination of new β-lactams with old β-lactamase inhibitors (BLIs), or the establishment of antibiotics with new BLIs, is the most general approach adopted, followed by the modification of the chemical structure of old antibiotics. The aim of this Special Issue is to promote the dissemination of studies evaluating the activity of novel antimicrobial agents against local and nationwide collections of Gram-negative clinical isolates. Studies characterizing resistance mechanisms responsible for the reduced activity of novel drugs will be prioritized. Surveillance studies are of paramount importance to monitor the emergence of novel antibiotic resistance and to provide useful data for the implementation of infection prevention and control and antibiotic stewardship measures.
Dr. Marco Coppi
Dr. Chaitanya Tellapragada
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cefiderocol
- ceftolozane/tazobactam
- ceftazidime/avibactam
- aztreonam/avibactam
- meropenem/vaborbactam
- imipenem/relebactam
- plazomicin
- eravacycline
- cepefime/taniborbactam
- delafloxacin
